You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
ADAMTS13 ACTIVITY WITH REFLEX TO INHIBITOR |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB1519 Geisinger Epic ID: 45315 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Platelet-poor plasma | |
Preferred collection container: |
||
Specimen required: |
1 mL frozen platelet-poor plasma | |
Special notes: |
Must be sent to lab immediately so specimen can be processed in 1 hour. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Using a plastic pipette, remove plasma, taking care to avoid the WBC/platelet buffy layer and place into a plastic vial. Centrifuge a second time and transfer platelet-poor plasma into a new plastic vial. Plasma must be free of platelets (<10,000/mcL). Freeze immediately and ship on dry ice. | |
Transport temperature: |
Frozen. | |
Specimen stability: |
Frozen -20°C: 21 days. | |
TEST DETAILS |
||
CPT code(s): |
85397 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
If ADAMTS13 Activity is < or = 0.30 IU/ml, then ADAMTS13 Inhibitor will be performed at an additional charge (CPT code(s): 85335). | |
Methodology: |
Immunoassay |
|
Synonyms: |
Quest code 145328 ADAMTS
|
|
Clinical significance: |
ADAMTS-13 is a zinc metalloprotease that cleaves ultra large vWF multimers. Studies have shown that low levels of ADAMTS-13 activity are associated with thrombotic thrombocytopenic purpura (TTP), a life-threatening hematological condition characterized by a low platelet count, microvascular thrombi, red cell fragmentation, and renal complications. Congenital TTP is a rare inherited disease caused by mutations within the ADAMTS-13 gene, which result in the production of non-functional protein. The acquired form of TTP is an autoimmune-like disorder caused by the development of autoantibodies to ADAMTS-13 that inhibits enzyme activity. | |